

Ibrutinib is safer than we think.

Joseph R. Slupsky, B.Sc., Ph.D.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool.

Ibrutinib works, but does using it set patients up for potential relapse due to causing increased genomic instability? This question is addressed in this issue of *Blood* by Morande *et al*¹, who provide convincing evidence that resolves a key safety issue surrounding the use of this drug, giving new insight into its mechanism of action.

Ibrutinib is increasingly used as the standard of care in the treatment of chronic lymphocytic leukemia (CLL) where recent studies of its long term use have shown both sustained efficacy and acceptable tolerability^{2,3}. Importantly, approximately a third of CLL patients relapse on ibrutinib therapy, and disease resistance in many of these cases is attributed to mutations in either Bruton's tyrosine kinase (BTK), the target of ibrutinib, or phospholipase $C\gamma 2$ (PLC $\gamma 2$), a principal target of BTK within B cells⁴. Worryingly, a pre-clinical study by Compagno *et al*⁵ suggested that inhibition of BTK increased genomic instability in normal and neoplastic B cells via a mechanism involving enhanced expression of activation-induced cytidine deaminase (AID). The implication here is that ibrutinib treatment may pre-destine CLL patients to drug resistance by causing increased genomic instability and consequent mutation in BTK and PLC $\gamma 2$. However, the findings of Compagno *et al*. were derived using MEC-1 cells, a CLL cell line derived from the malignant cells of a patient in prolymphocytoid transformation⁶. The effect of ibrutinib in primary CLL cells may not be the same, and this is exactly the data Morande *et al*¹ present. Using a combination of observations gained from primary CLL cells in *in-vivo* and *in-vitro* settings, these investigators find not only that ibrutinib treatment reduces levels of AID in cells from patients enrolled in a clinical trial, but also that it inhibits induction of AID expression in primary CLL cells that are being stimulated with CD40 Ligand (CD40L) and interleukin 4 (IL4). This latter finding is important because CD40L/IL4 is thought to be a key microenvironmental factor contributing to malignant clone survival and proliferation in CLL. When coupled to the former finding that ibrutinib limits AID expression *in vivo*, there is a strong suggestion that genomic instability caused by microenvironmental influence can be prevented by this drug. Thus, the worry that ibrutinib may sow the seeds of its own demise seems to be unfounded.

The role of microenvironment in CLL cannot be understated. By playing a role in survival and proliferation of the malignant cells in this disease, microenvironmental influences contribute in a major way to the expansion of clones that are resistant to therapy. Within this context ibrutinib targets BTK to simultaneously cause redistribution lymphocytosis by impeding the ability of CLL cells to reside within proliferation centres, and blocking the ability of these cells to respond to chemokines that stimulate entry/re-entry to this environment⁷. This effect on decreasing tumour burden is augmented by the reduced proliferation and enhanced death of CLL cells that is observed in patients being treated with ibrutinib⁸. Thus, our current understanding of ibrutinib's therapeutic effect is that it is mediated by removing CLL cells from proliferation centres and reducing their overall survival. Morande *et al*¹ add to this understanding by measuring AID expression in CLL cells that are Ki-67 positive, and showing that this population of cells is severely reduced after patients begin taking ibrutinib. This means that ibrutinib treatment blocks the means of creating mutation within CLL cells, as well as the means through which clones bearing mutation can be expanded. So why do patients on ibrutinib develop resistance, particularly that associated with mutation of BTK

and PLC γ 2? The answer to this is not clear but could be related to the amount of treatment received by a given patient prior to ibrutinib therapy. Such patients are particularly prone to developing ibrutinib resistance⁴, likely from clones already containing mutant BTK and PLC γ 2 that are reported present at low frequency⁹ rather than through *de-novo* mutagenesis.

So how does ibrutinib affect CLL cells in patients? This compound has a high degree of specificity for BTK, and the main downstream targets of this tyrosine kinase in B cells are PLC γ 2 and Wiskott-Aldrich syndrome protein (WASp), but this might not be all it does. To more fully understand how ibrutinib therapy impacts CLL cells, Morande *et al* isolated malignant cells bearing a phenotype associated with having a high proliferative index from CLL patients enrolled on a clinical trial before and during receipt the drug. They then performed a phospho-protein analysis on these cells and identified that ibrutinib treatment leads to dephosphorylation of JAK1 at Tyr1022, an event that deactivates the function of this kinase. Active JAK1 in cells stimulates the phosphatidylinositol 3-kinase (PI3K) pathway, and consistent with its deactivation in ibrutinib-treated CLL cells the authors observe changes in the phosphorylation of key proteins connected with this pathway that function in controlling proliferation and apoptosis. This could possibly account for the reduction of cells expressing Ki-67 and the increase in CLL cell death that is observed in these patients. The explanation for reduced AID expression is that JAK1 targets STAT6 for phosphorylation, which then translocates to the cell nucleus and is responsible for induction of AID expression. Indeed, Morande *et al* model this *in vitro* and show that ibrutinib treatment of CD40L/IL4-stimulated CLL cells reduces STAT6 phosphorylation and AID expression. Thus, a potentially new role for BTK can be applied that is different to its typical role in the BCR signalling pathway (Figure A). In this new role BTK is key to modulating JAK1 activation within CLL cells stationed within the microenvironment and exposed to CD40L/IL4 (Figure B). It is known that BTK becomes activated in CD40-stimulated B cells¹⁰, and within this context there may be new substrates, such as protein tyrosine phosphatases, that are able to dephosphorylate JAK1 and STAT6 and downregulate IL4 signalling. To find this out will require further experiments comparing the effect of ibrutinib on CLL cells incubated with IL4 alone and with CD40L/IL4.

This manuscript therefore sets the stage for further work into the mechanism of action of ibrutinib and similar compounds. These compounds can no longer be referred to as just BCR signalling pathway inhibitors, it seems they also affect a key pathway responsible for the development and expansion of resistant clones. Thus, ibrutinib is safer than we thought and may be most useful as a front line therapy.

Conflict of interest disclosure: The author is in receipt of funding from Verastem Inc., and has a collaborative relationship with the Netherlands Translational Research Center B.V. (NTRC)

References:

1. Morande PE, Sivina M, Uriepero A, et al. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. *Blood*. 2019:blood-2018-2009-876292. 10.1182/blood-2018-09-876292.
2. O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. *Blood*. 2018;131(17):1910-1919.
3. Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab. *Blood*. 2019:blood-2018-2008-870238. Prepublished on Mar 6 2019 as DOI 10.1182/blood-2018-08-870238.
4. Woyach JA, Furman RR, Liu T-M, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*. 2014;370(24):2286-2294.
5. Compagno M, Wang Q, Pighi C, et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. *Nature*. 2017;542:489.
6. Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. *Leuk Res*. 1999;23(2):127-136.
7. Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. *Leukemia*. 2014;28:2188-2196.
8. Burger JA, Li KW, Keating MJ, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. *JCI Insight*. 2017;2(2):e89904.
9. Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. *Nat Commun*. 2016;7:11589.
10. Brunner C, Avots A, Kreth HW, Serfling E, Schuster V. Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes. *Immunobiology*. 2002;206(4):432-440.




Figure. Central role of BTK in the regulation of BCR- and CD40L/IL4-induced signalling. A.) BTK is centrally involved in the BCR signalling pathway, sitting distal to Syk and PI3K δ , to phosphorylate and activate PLC γ 2 and WASp leading to further signal pathway activation and actin cytoskeleton rearrangements, respectively. **B.)** The mechanism of how BTK is activated by CD40 ligation is unknown, but could involve PI3K isoforms other than PI3K δ (involved in BCR signalling). Active BTK then potentially interacts with a protein tyrosine phosphatase, which subsequently dephosphorylates JAK1 and STAT6 to deactivate their function in promoting cell proliferation (through the PI3K pathway) and induction of AID expression. Ag, antigen; BLNK, B-cell linker protein; ERK, extracellular signal-regulated kinase; IL-4R, IL-4 receptor; NFAT, nuclear factor of activated T cells; P, phosphorylated tyrosine; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; TRAF, tumor necrosis factor receptor-associated factor.